Fifty companies spent months preparing for yesterday. The drug they’re racing to sell? One that 250 million Indians need — and almost none of them can afford.
The Price Crash
Novo Nordisk’s patent on semaglutide — the molecule behind Ozempic and Wegovy — expired in India on March 20. Within hours, Sun Pharma, Dr. Reddy’s, Zydus, Lupin, Cipla, and dozens more began launching generics. Monthly costs plunged from ₹11,000 to roughly ₹3,000–₹4,000. Natco Pharma undercut everyone at ₹1,296 a month — about $14.
That’s an 88% price drop overnight. For a drug proven to reduce major cardiovascular events by 20%, the math sounds transformative.
But here’s the number that complicates the celebration: of India’s 250 million obese adults, only 200,000 currently use GLP-1 drugs. That’s 0.08%.
The ₹3,000 Illusion
Even at generic prices, semaglutide requires indefinite monthly injections, regular doctor visits, and monitoring. At ₹3,000 a month — ₹36,000 a year — it remains out of reach for the vast majority who medically need it. India’s median monthly household income hovers around ₹15,000. A weakening rupee and rising inflation don’t help.
Meanwhile, analyst Salil Kallianpur warns that low prices and 50+ brands could fuel exactly the wrong kind of demand: “You may see direct pharmacy purchases, cosmetic or lifestyle use especially in urban markets — leading to misuse, poor titration, and eventually regulatory tightening.”
So the people who can pay will use it for vanity. The people who need it for survival still can’t afford it.
What Happens Next
India’s GLP-1 market is projected to hit ₹80 billion by 2030 — up from ₹15 billion today. Eli Lilly’s Mounjaro is already India’s top-selling drug by value. The obesity drug market is about to become a battlefield.
The patent cliff made semaglutide cheaper. Whether it makes it accessible is a different question — one that 50 brands and a ₹3,000 price tag haven’t answered yet.